LoginSignup
Novartis logo

Novartis

Stock
Stock
ISIN: CH0012005267
Ticker: NOVN
CH0012005267
NOVN

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 The next dividend will be paid on 11.03.2025

$1.972

CHART BY

Frequently asked questions

What is Novartis's market capitalization?

The market capitalization of Novartis is $187.00B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Novartis's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Novartis is 18.33. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Novartis?

Novartis's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $5.213. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Novartis's stock?

Currently, 29 analysts cover Novartis's stock, with a consensus target price of $115.15. Analyst ratings provide insights into the stock's expected performance.

What is Novartis's revenue over the trailing twelve months?

Over the trailing twelve months, Novartis reported a revenue of $44.31B.

What is the free float of Novartis's shares?

The free float of Novartis is 1.75B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$187.00B
EPS (TTM) 
$5.213
Free Float 
1.75B
P/E ratio (TTM) 
18.33
Revenue (TTM) 
$44.31B

Pricing

1D span
$104.72$107.01
52W span
$91.65$121.34

Analyst Ratings

The price target is $115.15 and the stock is covered by 29 analysts.

Buy

7

Hold

19

Sell

3

Information

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

ISIN
CH0012005267
Primary Ticker
NOVN

Knockouts

Join the conversation
Sign upLogin